Context Therapeutics Files 8-K

TL;DR

CTX shares: 8-K filed 9/17, covering shareholder votes & financials. Stay tuned.

AI Summary

Context Therapeutics Inc. filed an 8-K on September 17, 2024, reporting on matters submitted to a vote of security holders and financial statements. The company, incorporated in Delaware, is based in Philadelphia, PA, and operates in the pharmaceutical preparations industry.

Why It Matters

This filing indicates important corporate actions and financial reporting by Context Therapeutics Inc., which could influence investor decisions.

Risk Assessment

Risk Level: low — The filing is a routine 8-K reporting on corporate actions and financial statements, not indicating immediate significant risk.

Key Numbers

• 001-40654 — SEC File Number (Identifies the company's filing with the SEC.)
• 86-3738787 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Context Therapeutics Inc. (company) — Registrant
• September 17, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Philadelphia, Pennsylvania (location) — Principal executive offices
• 2001 Market Street, Suite 3915, Unit #15 (address) — Business address

FAQ

Key Financial Figures

• $0.001 — mon Stock CNTX The Nasdaq Stock Market $0.001 par value per share Indicate by check

Filing Documents

• cntx-20240917.htm (8-K) — 38KB
• exhibit31.htm (EX-3.1) — 8KB
• exhibit32.htm (EX-3.2) — 29KB
• 0001842952-24-000081.txt ( ) — 222KB
• cntx-20240917.xsd (EX-101.SCH) — 2KB
• cntx-20240917_lab.xml (EX-101.LAB) — 25KB
• cntx-20240917_pre.xml (EX-101.PRE) — 14KB
• cntx-20240917_htm.xml (XML) — 3KB

03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On September 17, 2024, Context Therapeutics Inc. (the "Company") held a Special Meeting of Stockholders (the "Special Meeting"). At the Special Meeting, the Company's stockholders approved, among other things, an amendment to the Company's Amended and Restated Certificate of Incorporation (the "Certificate") to increase the number of authorized shares of common stock from 100,000,000 to 200,000,000. A copy of the Certificate of Amendment to the Certificate to increase the number of authorized shares of common stock from 100,000,000 to 200,000,000 (the "Charter Amendment"), as filed with the Secretary of State of the State of Delaware on September 17, 2024, is attached as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference. A copy of the Company's Certificate, as amended and restated to reflect the Charter Amendment, is attached as Exhibit 3.2 to this Current Report on Form 8-K and is incorporated herein by reference.

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. As disclosed above in Item 5.03, the Company held the Special Meeting on September 17, 2024. As of July 22, 2024, the record date for the Special Meeting, there were 74,998,312 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Special Meeting, of which 43,251,969, or 57.67%, were present in person or represented by proxy, which constituted a quorum. The holders of shares of our common stock are entitled to one vote for each share held. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company's stockholders at the Special Meeting. Proposal 1. Approval of an Amendment to the Company's Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock. The Company's stockholders approved the proposed amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 200,000,000. The voting on this proposal is set forth below: For Against Abstentions Broker Non-Votes Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 200,000,000. 42,389,461 790,853 71,655 0 Proposal 2. Approval of One or More Adjournments. The Company's stockholders approved one or more adjournments of the Special Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there were insufficient votes to approve Proposal 1 at the time of the Special Meeting or in the absence of a quorum. For Against Abstentions Broker Non-Votes Approval of one or more adjournments of the Special Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to approve Proposal 1 at the time of the Spec

01. Exhibits

Item 9.01. Exhibits. (d) Exhibits Exhibit No. Description 3.1 Certificate of A m endment to the Amended and Restated Certificate of Incorporation , dated September 1 7 , 2024 3.2 Amended and Restated Certificate of Incorporation , as amended through Septemb er 17 , 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 17, 2024 Context Therapeutics Inc. By: /s/ Martin A. Lehr Name: Martin A. Lehr Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR